Presentation · Sep 2026 · PDF
Presentations & Publications
Achondroplasia
This page contains non-exhaustive scientific information about uses of products that have not yet been approved by regulatory authorities, as their efficacy and safety for these uses have not yet been established. The information is provided for educational and scientific exchange purposes, and does not suggest products should be used in a manner not consistent with their respective label approved by the regulatory authorities, which may differ by geography. Any publication reflects the state of knowledge at the time it was published. The information is not medical advice and cannot replace the independent medical judgement of a healthcare professional.
Presentation · Sep 2026 · PDF
BBIO-Infigratinib-ESPE 2026-Longer Term Results
Presentation · Sep 2026 · PDF
BBIO-Infigratinib-ESPE 2026-PROPEL3
Presentation · Jun 2026 · PDF
BBIO-ACH-ICCBH 2026-PROPEL-HRQoL
Presentation · Dec 2024 · PDF
Infigratinib - ISDS 2024 - Clinical Development Program Update
Presentation · Dec 2024 · PDF
BBIO - Infigratinib - PROPEL 2 Data Update and ACCEL Program Initiation
Presentation · Dec 2023 · PDF
Infigratinib - ESPE 2023 - Updated Six Month Results in Phase 2 Cohort 5 Study
Presentation · Dec 2023 · PDF
Infigratinib - ENDO 2023 - Updated Six Month Results in Phase 2 Cohort 5 Study
Presentation · Dec 2023 · PDF
Infigratinib - ENDO 2023 - Murine Models in Achondroplasia and Hypochondroplasia
Presentation · Dec 2023 · PDF
Infigratinib - ENDO 2023 - PROPEL, PROPEL 2 and PROPEL OLE
Presentation · Dec 2023 · PDF
Infigratinib - ENDO 2023 -Evaluation of Bone Mineral Density
Presentation · Dec 2023 · PDF
infigratinib - PROPEL2 Topline Results
Publication · Feb 2021 · PDF
Bone, Lifetime Impact of Achondroplasia: Current Evidence and Perspectives on the Natural History
Publication · 2019 · PDF
Orphanet Journal of Rare Diseases, Achondroplasia: A Comprehensive Clinical Review
Publication · Dec 2016 · PDF